ANDAOPHTHALMICOINTMENT
Approved
Jan 1995
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
BACITRACIN ZINC AND POLYMYXIN B SULFATE (bacitracin zinc and polymyxin b sulfate) by Bausch + Lomb is clinical pharmacology polymyxin b sulfate attacks gram-negative bacilli, including virtually all strains of pseudomonas aeruginosa and haemophilus influenzae species. First approved in 1995.
Drug data last refreshed 1w ago
Mechanism of Action
CLINICAL PHARMACOLOGY Polymyxin B sulfate attacks gram-negative bacilli, including virtually all strains of Pseudomonas aeruginosa and Haemophilus influenzae species. Bacitracin is active against most gram-positive bacilli and cocci including hemolytic streptococci.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on BACITRACIN ZINC AND POLYMYXIN B SULFATE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.